Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302/KEYNOTE-A39 trial

Thomas Powles, Michiel S. van der Heijden, Y. Loriot, Jens Bedke, Begoña P. Valderrama, Ganesh R. Iyer, Eiji Kikuchi, Jean Hoffman‐Censits, Christof Vulsteke, A. Drakaki, S. Rausch, Waddah Arafat, Se Hoon Park, Umang Swami, J.-R. Li, I. Duran, Seema Rao Gorla, Blanca Homet Moreno, Xin Yu, Yingdong Lu, Shilpa Gupta